What a melanocortin receptor actually looks like — and how it flips on

A system this old wrote its instructions in shape long before we could read them; the structures are us learning, at last, to see the letters.

For almost forty years we knew the melanocortin receptors the way you know someone by their reputation and never their face. We knew MC1R decided how dark skin ran; that MC4R sat at the centre of appetite; that MC2R answered the stress axis. We could measure what bound them and what they did. We had never actually seen one. Then, in a rush that ran from 2020 to 2023, the whole family sat for its portrait.^[1] This is what the pictures show.

The shape: seven helices and a shallow pocket

Every melanocortin receptor belongs to the largest and best-studied class of signalling proteins, the G-protein-coupled receptors. The shared design is old and economical: seven helices threaded back and forth through the cell membrane, packed into a bundle. The outward-facing end forms a shallow pocket where the signal binds; the inward-facing end, on the cytoplasmic side, is where the receptor hands its message to a G protein. What crosses the membrane is never the drug and never the hormone – only a change in shape, and then a second messenger.

Melanocortin receptors are among the smallest of these proteins – short outer tails, a compact pocket – which is part of why they proved hard to crystallise for so long, and part of why the whole family looks so alike. All five, MC1R through MC5R, are built on the one fold and grip their ligands the same way.^[3] That resemblance is not a detail. It is the origin of nearly every side effect in the field: a molecule shaped to fit one of these pockets will very nearly fit the other four.

First light: the cryo-EM wave

The breakthrough came from cryo-electron microscopy and a last round of crystallography arriving together. MC4R went first, in 2020 – a crystal structure caught with the blocker SHU9119 in its pocket.^[1] Within a year the field had the receptor switchedon: an active MC4R captured mid-signal, bound to setmelanotide and coupled to its G protein.^[2] MC1R, the pigment receptor, was resolved the same year with α-MSH and with afamelanotide in place;^[3]a second group solved four MC4R structures at once, including one holding a non-peptide drug;^[4] a third mapped the active receptor at high resolution.^[5]

The stragglers followed in 2023. MC2R – the odd receptor that answers only to ACTH – was solved together with the small partner protein it cannot work without;^[7] MC3R and MC5R, the two least-studied of the family, were resolved in the same paper.^[6] By the end of that year every one of the five had been seen. Since then the work has kept going: an engineered nanobody built to switch MC4R on by itself,^[9] and a 2025 set of the receptors with nothing bound at all, explaining why they hum with a little activity even when empty.^[8]

The calcium in the pocket

The first structure held a genuine surprise. Sitting inside the MC4R binding pocket, alongside the ligand, was a calcium ion – held in place by a small set of acidic receptor residues and reaching out to touch the ligand itself.^[1] This was not incidental. Calcium sharply raises how tightly agonists bind: take it away and agonist affinity falls by something like ten- to a hundred-fold. The ion is not packing material. It is part of the recognition.

The same calcium site turned up in structure after structure – MC1R, the other MC4R complexes – which told the field it was a family trait, not a quirk of one receptor.^[3][5] And it drew a sharp line between the two kinds of ligand. Agonists, the molecules that switch the receptor on, lean on the calcium. Antagonists occupy the very same pocket but do not need it.^[2] The distinction the whole system runs on – on versus off – is written partly in whether a single ion is invited to help.

How the switch flips

Every melanocortin peptide shares a four-residue core – His-Phe-Arg-Trp, the α-MSH signature – and the structures show it doing exactly what decades of pharmacology predicted: settling into the pocket, with the calcium bridging it to the receptor wall. What happens next is mechanical. On the far side of the membrane, transmembrane helix 6 swings outward at its cytoplasmic end, opening a cavity on the receptor’s inner face. Into that opening the Gs protein docks, and the familiar signal – cyclic AMP – begins.^[2]

It is worth being honest about the limits of the cartoon. The melanocortin receptors are unusual class-A GPCRs and break several of the tidy rules other receptors follow, so the exact set of internal “microswitches” is better read from the papers than recited as a fixed list.^[4] But the headline is solid and repeated across every structure: agonist in the pocket, TM6 out, G protein in.

Running it backwards

If activation is TM6 swinging out, blocking it is keeping TM6 in. The classic research antagonist SHU9119 binds the same pocket as an agonist, but a single bulky, unnatural side chain wedges against the hinge and stops the helix moving – the molecule occupies the switch without throwing it.^[2] There is a beautiful complication here: the very same SHU9119 that blocks MC4R actually activates MC1R, and it was caught doing so in the MC1R structure.^[3] A ligand is not simply an agonist or an antagonist. It is one or the other depending on which of the five pockets it finds itself in.

The body has its own blockers. AgRP and the pigment brake agouti (ASIP) are not merely competitors; they areinverse agonists, pushing the receptors below their resting idle rather than just keeping the natural signal out.^[10] That resting idle is real – the 2025 empty-receptor structures were solved precisely to explain the family’s built-in background activity, the thing an inverse agonist turns down.^[8] One honest gap remains: no one has yet captured an AgRP- or agouti-bound receptor directly, so how these brakes sit in the pocket is still read from function and modelling, not from a picture.

Beyond cAMP: what “biased” means

A receptor is not a simple on/off lamp with one wire. MC4R can talk through Gs and cyclic AMP, through a different G protein called Gq/11, and – strangest of all – straight to an ion channel. A biased agonist is one that leans on some of these routes more than others, because the particular shape it locks the receptor into favours one exit over another. The approved drug setmelanotide, for one, is described as biased toward the Gq/11 route.^[5]

The strangest route skips G proteins entirely. In hypothalamic neurons, MC4R can open and close the potassium channel Kir7.1 directly: α-MSH closes it and AgRP opens it, changing whether the neuron fires – without a G protein in between.^[11] The finding was unusual enough to be argued over for years; it now has support from several groups and, as of 2026, a structure of Kir7.1 with MC4R to give the mechanism a shape.^[12]It is a good reminder that these receptors are still handing us surprises.

Why MC2R needs a chaperone

One receptor refused to behave like the others. MC2R, the adrenal receptor for ACTH, cannot even reach the cell surface on its own, let alone bind its hormone. It needs a small partner protein, MRAP1, and the 2023 structure showed why: MRAP1 wraps across the receptor like a seat-belt, reshaping the entrance so that ACTH – much larger than the little His-Phe-Arg-Trp core – can be read.^[7] It is the clearest case in the family of a receptor that is only half a machine by itself.

A close cousin of that helper, MRAP2, tunes MC4R and MC3R instead of MC2R, shifting how strongly they signal and how they pair up.^[13] That complex has not yet been solved atomically; for now it is known from function. The distinction is worth keeping straight, because the two are easy to confuse: MRAP1 is MC2R’s indispensable partner, MRAP2 is the modulator of the appetite receptors.

Why the pictures matter

Structures are not decoration; they change what can be built. They already explain the drugs we have – why setmelanotide switches MC4R on while the almost-identical SHU9119 does not comes straight out of comparing the two in the same pocket,^[2][5] and why a small non-peptide molecule can be made to fit at all was answered by catching one in the act.^[4] They also explain the field’s central frustration. The shared pocket and the shared calcium trick, so elegant across MC1R–MC5R, are exactly why an MC4R appetite drug spills onto MC1R and darkens the skin, or brushes the adrenal MC2R.^[6]

The encouraging part is that the pictures are starting to solve the problem they revealed. Structure-guided redesign of setmelanotide’s core has already produced a compound with more than a hundred-fold preference for MC4R over MC1R – an early, deliberate attempt to keep the appetite effect and leave the pigment alone.^[14] And wholly new kinds of key are being cut: an engineered nanobody that switches MC4R on by itself, a tool that did not exist before the structures made it thinkable.^[9] A system we could only describe five years ago is one we are beginning to design against.